Fact Sheet: President Donald J. Trump Announces Lower Drug Prices for All 50 State Medicaid Programs

Summary: This White House fact sheet announces that all 50 states' Medicaid programs will benefit from Most-Favored-Nation (MFN) drug pricing under the "GENEROUS Medicaid Payment Model," building on prior pharmaceutical pricing agreements. The Medicaid model: Participating manufacturers will provide rebates ensuring Medicaid drug prices don't exceed MFN levels, covering hundreds of drugs across major classes including oncology, diabetes, and asthma treatments. Medicaid programs have already received 1 million free prescriptions of Eliquis (a heart disease medication) under the deals. The Council of Economic Advisers estimates $64.3 billion in savings over the next decade — $36.6 billion federal, $27.6 billion state. Broader MFN and TrumpRx impact: Since its February 2026 launch, TrumpRx.gov has generated over $700 million in consumer savings, including on obesity and infertility medications. Since July 2026, seniors gained access to GLP-1 drugs for obesity at $50/month; 600,000 seniors saved a combined $216 million in the program's first two months. CEA estimates total MFN-related savings could reach $600 billion over the next decade. Timeline of MFN policy actions: May 2025: Executive order directing MFN pricing action. July 2025: Letters sent to 17 major pharmaceutical manufacturers. September 2025: First MFN agreement announced, with Pfizer. December 2025: A separate agreement with the UK to raise its drug prices by 25%; nine additional manufacturer agreements announced. February 2026: TrumpRx.gov launched. August 2026: Nine more manufacturer agreements announced. As of this release, 26 manufacturers have signed MFN agreements, covering 89% of the branded drug market (list includes Pfizer, AstraZeneca, Eli Lilly, Novo Nordisk, Merck, Johnson & Johnson, and others). Additional ask: Calls on Congress to pass a "Great Healthcare Plan" addressing drug prices, insurance premiums, and price transparency. Note: This is an administration-authored release; the savings estimates and framing reflect the administration's own characterization rather than independent verification.